19:55 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Erasca launches to target cancer drivers

Oncology company Erasca Inc. (San Diego, Calif.) launched Dec. 18 with an untranched $42 million series A round and a basket of discovery programs targeting undisclosed cancer drivers. The financing was co-led by founding investors...
13:02 , Dec 18, 2018 |  BC Extra  |  Financial News

Erasca launches to target cancer drivers

Oncology company Erasca Inc. (San Diego, Calif.) launched Tuesday with an untranched $42 million series A round and a basket of discovery programs targeting undisclosed cancer drivers. The financing was co-led by founding investors City...
20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma; brain cancer; lung cancer; neuroendocrine tumors Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural...
22:58 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
20:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...
13:05 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Merck halts Phase III trial of AD candidate verubecestat

Merck & Co. Inc. (NYSE:MRK) stopped the double-blind, international Phase III APECS trial of verubecestat (MK-8931) to treat prodromal Alzheimer’s disease after an external DMC said it was unlikely the trial would establish a positive...
00:09 , Feb 14, 2018 |  BC Extra  |  Clinical News

Merck halts Phase III trial of AD candidate

Merck & Co. Inc. (NYSE:MRK) stopped the Phase III APECS trial of verubecestat (MK-8931) to treat prodromal Alzheimer’s disease after an external DMC said it was unlikely the trial would establish a positive benefit-risk profile...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
14:16 , Apr 18, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mouse models with intestinal organoids containing LGR5 -positive CSCs could be used to probe the cells’ role and identify new therapeutic targets in metastatic colorectal cancer. The organoids were generated by culturing...
20:15 , Feb 16, 2017 |  BC Week In Review  |  Company News

Bionomics, Merck deal

Bionomics will receive a $10 milestone payment from Merck under a 2014 deal granting the pharma exclusive, worldwide development and commercialization rights to Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and...